Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans

Psychoneuroendocrinology

Volumn 52, Issue 1, 2015, Pages 281-288

  Bershad, Anya K ^a   Jaffe, Jerome H ^b   Childs, Emma ^a   de Wit, Harriet ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Buprenorphine; Cortisol; Opioid; Stress; TSST

Indexed keywords

BUPRENORPHINE; HYDROCORTISONE; PLACEBO; NARCOTIC ANALGESIC AGENT;

ADULT; ANXIETY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MENTAL STRESS; MOOD; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; PUBLIC SPEAKING; RANDOMIZED CONTROLLED TRIAL; SALIVA ANALYSIS; SELF REPORT; SIGNAL TRANSDUCTION; SOCIAL STRESS; TASK PERFORMANCE; TRIER SOCIAL STRESS TEST; METABOLISM; PREVENTION AND CONTROL; YOUNG ADULT;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; HYDROCORTISONE; MALE; STRESS, PSYCHOLOGICAL; YOUNG ADULT;

EID: 84922662872     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.12.004     Document Type: Article

References (45)

1. Bodnar R.J. Endogenous opiates and behavior: 2012. Peptides 2013, 50:55-95.
2. Chong R.Y., Oswald L., Yang X., Uhart M., Lin P.-I., Wand G.S. The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 2005, 31:204-211.
3. Compton W.M., Volkow N.D. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006, 81:103-107.
4. Drolet G., Dumont A.C., Gosselin I., Kinkead R., Laforest S., Trottier J.-F. Role of endogenous opioid system in the regulation of the stress response. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2001, 25:729-741.
5. Eisenman A.J., Fraser H., Brooks J.W. Urinary excretion and plasma levels of 17-hydroxycorticosteroids during a cycle of addiction to morphine. J. Pharmacol. Exp. Ther. 1961, 132:226-231.
6. Eisenman A.J., Fraser H., Sloan J., Isbell H. Urinary 17-ketosteroid excretion during a cycle of addiction to morphine. J. Pharmacol. Exp. Ther. 1958, 124:305-311.
7. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview for DSM-IV® Axis I Disorders (SCID-I), Clinician Version, Administration Booklet 2012, American Psychiatric Pub.
8. Fischman M.W., Foltin R.W. Utility of subjective effects measurements in assessing abuse liability of drugs in humans. Br. J. Addict. 1991, 86:1563-1570.
9. Funk D., Coen K., Lê A. The role of kappa opioid receptors in stress-induced reinstatement of alcohol seeking in rats. Brain Behav. 2014, 4:356-367.
10. Gaab J., Rohleder N., Nater U., Ehlert U. Psychological determinants of the cortisol stress response: the role of anticipatory cognitive appraisal. Psychoneuroendocrinology 2005, 30:599-610.
11. Good A.J., Westbrook R. Effects of a microinjection of morphine into the amygdala on the acquisition and expression of conditioned fear and hypoalgesia in rats. Behav. Neurosci. 1995, 109:631.
12. Guillemin R., Vargo T., Rossier J., Minick S., Ling N., Rivier C., Vale W., Bloom F. Beta-endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland. Science 1977, 197:1367-1369.
13. Herman B.H., Panksepp J. Effects of morphine and naloxone on separation distress and approach attachment: evidence for opiate mediation of social affect. Pharmacol. Biochem. Behav. 1978, 9:213-220.
14. Hill H.E., Belleville R.E., Wikler A. Studies on anxiety associated with anticipation of pain: II. Comparative effects of pentobarbital and morphine. AMA Arch. Neurol. 1955, 73:602-608.
15. Hill H.E., Kornetsky C.H., Flanary H.G., Wikler A. Studies on anxiety associated with anticipation of pain: I. Effects of morphine. AMA Arch. Neurol. 1952, 67:612-619.
16. Ide S., Sora I., Ikeda K., Minami M., Uhl G.R., Ishihara K. Reduced emotional and corticosterone responses to stress in μ-opioid receptor knockout mice. Neuropharmacology 2010, 58:241-247.
17. Ipser J.C., Terburg D., Syal S., Phillips N., Solms M., Panksepp J., Malcolm-Smith S., Thomas K., tein D.J., van Honk J. Reduced fear-recognition sensitivity following acute buprenorphine administration in healthy volunteers. Psychoneuroendocrinology 2013, 38:166-170.
18. Kahveci N., Gulec G., Ozluk K. Effects of intracerebroventricularly injected morphine on anxiety, memory retrieval and locomotor activity in rats: involvement of vasopressinergic system and nitric oxide pathway. Pharmacol. Biochem. Behav. 2006, 85:859-867.
19. Kalin N.H., Shelton S.E., Barksdale C.M. Opiate modulation of separation-induced distress in non-human primates. Brain Res. 1988, 440:285-292.
20. Kirschbaum C., Kudielka B.M., Gaab J., Schommer N.C., Hellhammer D.H. Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis. Psychosom. Med. 1999, 61:154-162.
21. Kirschbaum C., Pirke K.-M., Hellhammer D.H. The 'Trier Social Stress Test' - a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 1993, 28:76-81.
22. Komatsu H., Ohara A., Sasaki K., Abe H., Hattori H., Hall F.S., Uhl G.R., Sora I. Decreased response to social defeat stress in mu-opioid receptor knockout mice. Pharmacol. Biochem. Behav. 2011, 99:676-682.
23. Kosten T.R., Morgan C., Kosten T.A. Depressive symptoms during buprenorphine treatment of opioid abusers. J. Subst. Abuse Treat. 1990, 7:51-54.
24. Kreek M., Hartman N. Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids, and toxicity. Annals of the New York Academy of Sciences 1982, 398:151-172.
25. Kudielka B.M., Hellhammer D.H., Kirschbaum C., Harmon-Jones E., Winkielman P. Ten years of research with the Trier Social Stress Test-revisited. Social Neuroscience: Integrating Biological and Psychological Explanations of Social Behavior 2007, 56-83.
26. Land B.B., Bruchas M.R., Lemos J.C., Xu M., Melief E.J., Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J. Neurosci. 2008, 28:407-414.
27. Leander J. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 1987, 26:1445-1447.
28. Lijffijt M., Hu K., Swann A.C. Stress modulates illness-course of substance use disorders: a translational review. Front Psychiatry 2014, 5:1-20.
29. Mansour A., Fox C.A., Akil H., Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 1995, 18:22-29.
30. Maremmani I., Pacini M., Pani P.P. Effectiveness of buprenorphine in double diagnosed patients. Buprenorphine as psychothropic drug. Heroin Addict. Relat. Clin. Probl. 2006, 8:31-48.
31. McLaughlin J.P., Li S., Valdez J., Chavkin T.A., Chavkin C. Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology 2005, 31:1241-1248.
32. McNair D., Lorr M., Droppleman L. POMS, Profile of Mood States 1971, Educational and Industrial Testing Services, San Diego, CA.
33. Mendelson J., Upton R.A., Everhart E.T., Jones R.T. Bioavailability of sublingual buprenorphine. J. Clin. Pharmacol. 1997, 37:31-37.
34. Panksepp J., Herman B., Conner R., Bishop P., Scott J. The biology of social attachments: opiates alleviate separation distress. Biol. Psychiatry 1978, 607-618.
35. Peckys D., Landwehrmeyer G. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a in situ hybridization study. Neuroscience 1999, 88:1093-1135.
36. Schmidt A., Borgwardt S., Gerber H., Wiesbeck G.A., Schmid O., Riecher-Rossler A., Smieskova R., Lang U.E., Walter M. Acute effects of heroin on negative emotional processing: relation of amygdala activity and stress-related responses. Biol. Psychiatry 2013, 289-296.
37. Schuman-Olivier Z., Albanese M., Nelson S.E., Roland L., Puopolo F., Klinker L., Shaffer H.J. Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers. J. Subst. Abuse Treat. 2010, 39:41-50.
38. Simonin F., Gaveriaux-Ruff C., Befort K., Matthes H., Lannes B., Micheletti G., Mattei M.-G., Charron G., Bloch B., Kieffer B. Kappa-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7006-7010.
39. Sinha R. How does stress increase risk of drug abuse and relapse?. Psychopharmacology (Berlin) 2001, 158:343-359.
40. Spanagel R., Noori H.R., Heilig M. Stress and alcohol interactions: animal studies and clinical significance. Trends Neurosci. 2014, 37:219-227.
41. Spielberger, C.D., Gorsuch, R.L., and Lushene., R.E., 1970. "Manual for the state-trait anxiety inventory.".
42. Stein D.J., van Honk J., Ipser J., Solms M., Panksepp J. Opioids: from physical pain to the pain of social isolation. CNS Spectr. 2007, 12:669-670.
43. Wilson M.A., Junor L. The role of amygdalar mu-opioid receptors in anxiety-related responses in two rat models. Neuropsychopharmacology 2008, 33:2957-2968.
44. Yamamoto M., Komori T., Matsumoto T., Zhang K., Miyahara S., Shizuya K., Okazaki Y. Effects of single and repeated prolonged stress on mu-opioid receptor mRNA expression in rat gross hypothalamic and midbrain homogenates. Brain Res. 2003, 980:191-196.
45. Zhang G.F., Ren Y.P., Sheng L.X., Chi Y., Du W.J., Guo S., Zhang H.X. Dysfunction of the hypothalamic-pituitary-adrenal axis in opioid dependent subjects: effects of acute and protracted abstinence. Am. J. Drug Alcohol 2008, 34:760-768.